Metagenomi Inc (MGX) Stock Price, Quote & News

Company Profile

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medic...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 871 4880

Website: metagenomi.co

Address:

5959 Horton Street, 7th Floor, Emeryville, United States

Diverstj981 Jun. 18 at 2:08 PM

$MGX Dead money here

0 · Reply

frontiere Jun. 17 at 12:42 PM

When things get too asymmetric, they become a no-brainer. Especially on a long side (more caveats if short). C&Gt / Gtx / Gene editing basket is oversold, has been my thesis since Dec 2024. $VERV Verve acquired today by $LLY Eli Lilly for $10.50 cash+$3.00 CVR, vs $6.27 yesterday closing price and still below March 2024 levels. Right now Long $MGX Metagenomi since 2024 and trading actively, $SRPT Sarepta since yesterday, $LXEO Lexeo…

0 · Reply

MikeEhrmantraut Jun. 12 at 5:16 PM

$MGX asymmetric reward vs risk opportunity here similar to when $CTMX had a MC of $32M when it was trading at 40 cents in April.

1 · Reply

Ned_Nosurname May. 24 at 1:26 AM

$MGX (OT) New data from Dr. Liu's group. It is the result of more than three years of continuously improving CASTs. A version, dubbed evoCAST, improves the editing efficiency from less than 0.1% of human cells to between ~10%-30% of cells. One major hurdle of turning the evoCAST into a therapeutic solution that is able to insert large genes is the size and collective complexity of the seven proteins that comprise the system. But Dr. Liu said the scientists are working on streamlining the system further. https://pubmed.ncbi.nlm.nih.gov/40373119/

1 · Reply

StillSendingIt May. 15 at 11:19 PM

$MGX slow death.

0 · Reply

JarvisFlow May. 15 at 12:30 PM

Chardan Capital has adjusted their stance on Metagenomi ( $MGX ), setting the rating to Buy with a target price of 13 → 12.

0 · Reply

Ned_Nosurname May. 14 at 8:42 PM

$MGX https://www.globenewswire.com/news-release/2025/05/14/3080921/0/en/Metagenomi-Presents-Data-Highlighting-Advancements-in-Next-Generation-Genome-Editing-Technologies-at-ASGCT-Annual-Meeting-2025.html

0 · Reply

Thestocktraderhubzee May. 14 at 10:23 AM

WATCHLIST MAY 14 2025. $RENB Renovaro Agrees On Terms For Exclusive Collaboration Agreement With Amsterdam UMC To Jointly Evaluate And Develop Blood Platelet RNA Diagnostics $MGX Metagenomi Announced The Presentation Of Three Abstracts At The American Society Of Gene & Cell Therapy Annual Meeting $SRPT Japanese Ministry Of Health, Labour, And Welfare Approved Sarepta Theraperutics' ELEVIDYS For Treatment Of Duchenne Muscular Dystrophy Under Conditional And Time-Limited Approval Pathway In Japan $UP Wheels Up Experience Announces Multi-Series Global Partnership With United Autosports To Deliver Customers Unmatched Motorsport Experiences $UBER Uber Announces Proposed Private Placement Of $1B Of Exchangeable Senior Senior Notes Due 2028

0 · Reply

Ned_Nosurname May. 2 at 10:43 PM

$SGMO Others are working on targeted genomic integration of large DNA cargoes. For example, both $MGX and $CRSP are developing CRISPR-associated transposases. While data from either is limited, at ASGCT '24, Dr. Liu's group showed an evolved CAST system supports ~10-30% integration efficacy of kilobase-size DNA cargoes across multiple human genomic sites.

2 · Reply

Zyrte May. 1 at 3:06 PM

$MGX FANTASTIC news from yesterday!! https://www.defenseworld.net/2025/04/30/geode-capital-management-llc-has-2-12-million-stock-position-in-metagenomi-inc-nasdaqmgx.html Goal $30?

0 · Reply

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 13, 2025, 4:30 PM EDT - 6 weeks ago

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 7:00 AM EDT - 7 weeks ago

Metagenomi to Present at Upcoming Scientific Meetings

Mar 17, 2025, 4:05 PM EDT - 3 months ago

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Mar 13, 2025, 6:19 AM EDT - 3 months ago

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Feb 11, 2025, 8:55 AM EST - 4 months ago

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Jan 16, 2025, 8:55 AM EST - 5 months ago

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Jan 15, 2025, 8:55 AM EST - 5 months ago

Metagenomi Announces New Appointment to its Board of Directors

Jan 8, 2025, 4:05 PM EST - 5 months ago

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 6:30 PM EST - 6 months ago

Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”

Dec 9, 2024, 9:16 PM EST - 7 months ago

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

Nov 25, 2024, 11:30 AM EST - 7 months ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Nov 25, 2024, 9:56 AM EST - 7 months ago

FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

Nov 24, 2024, 9:37 AM EST - 7 months ago

MGX Deadline: Rosen Law Firm Urges Metagenomi, Inc. (NASDAQ: MGX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Nov 23, 2024, 5:15 PM EST - 7 months ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Affected Stockholders Are Urged To Assist The Schall Law Firm

Nov 23, 2024, 1:00 PM EST - 7 months ago

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

Nov 22, 2024, 11:59 AM EST - 7 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

Nov 21, 2024, 12:00 PM EST - 7 months ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Nov 20, 2024, 12:41 PM EST - 7 months ago

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights – MGX

Nov 20, 2024, 11:00 AM EST - 7 months ago

The Schall Law Firm Invites Investor Participation In A Fraud Case Against Metagenomi Inc

Nov 18, 2024, 1:30 PM EST - 7 months ago

The Schall Law Firm Invites Investors To Join A Fraud Case Against Metagenomi Inc

Nov 17, 2024, 3:00 PM EST - 7 months ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

Nov 14, 2024, 9:18 PM EST - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

Nov 13, 2024, 1:15 PM EST - 7 months ago

Metagenomi, Inc. Is Being Sued For Violating Securities Regulations And Shareholders With Losses Are Urged To Help The Schall Law Firm

Nov 11, 2024, 4:00 PM EST - 8 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

Nov 11, 2024, 2:45 PM EST - 8 months ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Assist The Schall Law Firm

Nov 9, 2024, 12:30 PM EST - 8 months ago

Metagenomi, Inc. May Have Violated Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Nov 4, 2024, 11:00 AM EST - 8 months ago

The Schall Law Firm Encourages Investor Participation In A Fraud Case Against Metagenomi Inc

Diverstj981 Jun. 18 at 2:08 PM

$MGX Dead money here

0 · Reply

frontiere Jun. 17 at 12:42 PM

0 · Reply

MikeEhrmantraut Jun. 12 at 5:16 PM

$MGX asymmetric reward vs risk opportunity here similar to when $CTMX had a MC of $32M when it was trading at 40 cents in April.

1 · Reply

Ned_Nosurname May. 24 at 1:26 AM

1 · Reply

StillSendingIt May. 15 at 11:19 PM

$MGX slow death.

0 · Reply

JarvisFlow May. 15 at 12:30 PM

Chardan Capital has adjusted their stance on Metagenomi ( $MGX ), setting the rating to Buy with a target price of 13 → 12.

0 · Reply

Ned_Nosurname May. 14 at 8:42 PM

0 · Reply

Thestocktraderhubzee May. 14 at 10:23 AM

0 · Reply

Ned_Nosurname May. 2 at 10:43 PM

2 · Reply

Zyrte May. 1 at 3:06 PM

$MGX FANTASTIC news from yesterday!! https://www.defenseworld.net/2025/04/30/geode-capital-management-llc-has-2-12-million-stock-position-in-metagenomi-inc-nasdaqmgx.html Goal $30?

0 · Reply

Midlevelstrader Apr. 25 at 6:36 PM

$MGX

0 · Reply

Midlevelstrader Apr. 23 at 6:28 PM

$MGX What's the forecast on this?

1 · Reply

Ned_Nosurname Apr. 22 at 11:48 PM

$EDIT $MGX $BEAM https://endpts.com/china-biotech-startup-huidagene-uses-crispr-in-brain-for-rare-ailment/

3 · Reply

Diverstj981 Apr. 21 at 8:48 PM

$MGX Not much interest, almost no volume since January.

0 · Reply

Midlevelstrader Apr. 19 at 4:20 AM

$MGX How come analysts put this in the $13 range

1 · Reply

Tuffmut Apr. 12 at 1:51 PM

$MGX Liking this set up for next week.

1 · Reply

Tuffmut Apr. 9 at 11:36 PM

$MGX I just made the bid go up to $1.57 Lets see what happens here.

0 · Reply

11thestate Apr. 7 at 10:42 AM

$MGX stockholders filed a claim against Metagenomi for misrepresenting its collaboration with Moderna's strength and long-term viability. You can join this case to be notified about potential recovery: https://11th.com/cases/metagenomi-investor-suit

0 · Reply

Costi2024 Apr. 4 at 7:10 PM

$MGX any reason for the jump today?

0 · Reply

Market Cap	53.08M
Revenue (ttm)	52.30M
Net Income (ttm)	-78.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-149.25%
Debt to Equity Ratio	0.00

Volume	564,700
Avg Vol	378,834
Day's Range	N/A - N/A
Shares Out	37.38M
Stochastic %K	63%
Beta	-0.34
Analysts	Strong Sell
Price Target	$12.80